| NCT06286046 | A Study of Mitapivat in Participants With Sickle Cell Disease and Nephropathy | NOT_YET_RECRUITING | PHASE2 | 2026-03 | 2028-12 | 2027-05 |
| NCT07075640 | A Study to Determine the Safety and Tolerability of AG-236 and How it is Absorbed, Broken Down, and Eliminated From the Body in Healthy Participants | RECRUITING | PHASE1 | 2025-07-07 | 2025-12-12 | 2025-10-17 |
| NCT06924970 | A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD) | RECRUITING | PHASE2 | 2025-05-01 | 2027-05 | 2026-05 |
| NCT06745271 | A Study to Determine How Tebapivat is Absorbed, Broken Down, and Removed From the Body and the Extent to Which Tebapivat is Made Available in the Body in Healthy Participants | COMPLETED | PHASE1 | 2024-12-20 | 2025-02-21 | 2025-02-21 |
| NCT06648824 | Study of How Mitapivat Affects Midazolam Blood Levels in Healthy Participants | COMPLETED | PHASE1 | 2024-10-17 | 2024-12-03 | 2024-12-03 |
| NCT06286033 | Single and Multiple Ascending Dose Study and Food Effect Study for AG181 | RECRUITING | PHASE1 | 2024-02-20 | 2025-10-01 | 2025-10-01 |
| NCT05777993 | A Study to Provide Continued Access to Mitapivat for Participants Who Previously Completed an Agios-Sponsored Mitapivat Study | ENROLLING_BY_INVITATION | PHASE4 | 2023-07-06 | 2029-08 | 2029-08 |
| NCT05610657 | A Pharmacokinetic Study of Mitapivat in Participants With Moderate Hepatic Impairment Compared to Matched Healthy Control Participants With Normal Hepatic Function | COMPLETED | PHASE1 | 2023-01-10 | 2023-07-21 | 2023-07-21 |
| NCT05490446 | A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS) | RECRUITING | PHASE2 | 2022-11-07 | 2028-11 | 2025-11 |
| NCT05144256 | A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Regularly Transfused, Followed by a 5-Year Extension Period | ACTIVE_NOT_RECRUITING | PHASE3 | 2022-06-08 | 2029-06 | 2024-05-03 |
| NCT05175105 | A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Not Regularly Transfused, Followed by a 5-Year Extension Period | ACTIVE_NOT_RECRUITING | PHASE3 | 2022-06-06 | 2030-01 | 2024-12-13 |
| NCT05031780 | A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP) | ACTIVE_NOT_RECRUITING | PHASE2, PHASE3 | 2022-02-11 | 2030-02 | 2025-10 |
| NCT04770753 | A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-NTDT) | ACTIVE_NOT_RECRUITING | PHASE3 | 2021-12-20 | 2028-12 | 2023-11-13 |
| NCT04770779 | A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT) | ACTIVE_NOT_RECRUITING | PHASE3 | 2021-11-30 | 2029-06 | 2024-04-11 |
| NCT04696393 | A Study to Compare the Pharmacokinetics and Safety of Mitapivat 100 mg Tablet Formulation With Mitapivat 2 × 50 mg Tablet Formulation in Healthy Adult Participants | COMPLETED | PHASE1 | 2021-01-06 | 2021-03-19 | 2021-03-19 |
| NCT04565678 | A Study to Assess the Relative Bioavailability and Effect of Food on the Coated Granule Formulation of Mitapivat in Healthy Participants | COMPLETED | PHASE1 | 2020-09-21 | 2020-12-03 | 2020-12-03 |
| NCT04536792 | A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunteers and in Participants With Sickle Cell Disease | COMPLETED | PHASE1 | 2020-07-10 | 2023-12-19 | 2023-12-19 |
| NCT04472832 | A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Mitapivat (AG-348) in Healthy Adult Participants | COMPLETED | PHASE1 | 2020-06-17 | 2020-11-23 | 2020-11-23 |
| NCT04145128 | A Study to Evaluate AG-881 in Healthy Japanese and Non-Asian Participants | COMPLETED | PHASE1 | 2019-10-02 | 2019-12-18 | 2019-12-11 |
| NCT04128787 | A Study to Compare the Relative Bioavailability of Two AG-881 Formulations and Evaluate the Effect of Food and Omeprazole on the Pharmacokinetics of AG-881 | COMPLETED | PHASE1 | 2019-09-30 | 2019-12-18 | 2019-12-18 |
| NCT04015687 | A Study to Evaluate the Effect of AG-881 on the Pharmacokinetics of a Single Dose of Lamotrigine in Healthy Adults | COMPLETED | PHASE1 | 2019-07-15 | 2019-10-09 | 2019-10-09 |
| NCT03991312 | Study to Evaluate the Effect of Multiple Doses of Itraconazole and Rifampin on the Single-Dose Pharmacokinetics of Mitapivat Sulfate (AG-348) in Healthy Adult Participants | COMPLETED | PHASE1 | 2019-06-20 | 2019-09-10 | 2019-08-14 |
| NCT03834584 | A Study of AG-636 in the Treatment of Subjects With Advanced Lymphoma | TERMINATED | PHASE1 | 2019-05-24 | 2020-06-17 | 2020-06-17 |
| NCT03960502 | A Safety and Pharmacokinetic Study of AG-881 in Healthy Male Participants Following Administration of a Single Oral Dose of [14C] AG-881 and Concomitant Intravenous Microdose of [13C315N3] AG-881 | COMPLETED | PHASE1 | 2019-05-16 | 2019-09-07 | 2019-09-07 |
| NCT03853798 | Extension Study of AG-348 in Adult Participants With Pyruvate Kinase Deficiency Previously Enrolled in AG-348-006 or AG348-C-007 | COMPLETED | PHASE3 | 2019-03-21 | 2024-07-03 | 2024-07-03 |
| NCT03692052 | A Study to Determine the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AG-348 in Adult Participants With Non-transfusion-dependent Thalassemia | ACTIVE_NOT_RECRUITING | PHASE2 | 2019-03-20 | 2030-09-30 | 2020-08-20 |
| NCT03548220 | A Study to Evaluate Efficacy and Safety of AG-348 in Not Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD) | COMPLETED | PHASE3 | 2018-08-09 | 2020-10-09 | 2020-10-09 |
| NCT03559699 | A Study Evaluating the Efficacy and Safety of AG-348 in Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD) | COMPLETED | PHASE3 | 2018-06-26 | 2020-11-12 | 2020-11-12 |
| NCT03703505 | A Study to Evaluate the Absorption, Distribution, Metabolism, Excretion and Absolute Bioavailability of AG-348 in Healthy Male Participants Following Administration of a Single Oral Dose of [14C]AG-348 and Concomitant Single Intravenous Microdose of [13C6]AG-348 | COMPLETED | PHASE1 | 2018-05-24 | 2018-06-04 | 2018-06-01 |
| NCT03397329 | Study to Evaluate the Relative Bioavailability and Safety of the AG-348 Tablet and Capsule Formulations in Healthy Adults | COMPLETED | PHASE1 | 2017-10-03 | 2017-11-13 | 2017-11-13 |
| NCT03282513 | A Study of AG-120 (Ivosidenib) in Subjects With Mild or Moderate Hepatic Impairment or Normal Hepatic Function | COMPLETED | PHASE1 | 2017-09-26 | 2018-03-31 | 2018-03-31 |
| NCT03250598 | Study to Evaluate the Pharmacokinetics, Safety, and QTc Effect of AG-348 in Healthy Subjects of Japanese Origin and Non-Asian Origin | COMPLETED | PHASE1 | 2017-08-09 | 2017-10-09 | 2017-10-02 |
| NCT03071770 | Japanese Bridging Study of Ivosidenib (AG-120) in Healthy Subjects | COMPLETED | PHASE1 | 2017-03-31 | 2017-09-06 | 2017-05-09 |
| NCT02831972 | Drug-Drug Interaction Study of AG120 in Healthy Subjects | COMPLETED | PHASE1 | 2016-06 | 2016-10 | 2016-09 |
| NCT02630927 | A Safety and Tolerability Study of AG-519 in Healthy Subjects | TERMINATED | PHASE1 | 2015-12 | 2016-12 | 2016-12 |
| NCT02579707 | Food Effect Study of AG120 in Healthy Subjects | COMPLETED | PHASE1 | 2015-10 | 2016-06 | 2016-02 |
| NCT02492737 | Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation | COMPLETED | PHASE1 | 2015-08-07 | 2018-03-21 | 2018-03-21 |
| NCT02476916 | A Study of AG-348 in Adult Participants With Pyruvate Kinase (PK) Deficiency | COMPLETED | PHASE2 | 2015-06-26 | 2025-04-02 | 2017-05-08 |
| NCT02489513 | Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-AG-120 | COMPLETED | PHASE1 | 2015-06 | 2015-10 | 2015-09 |
| NCT02218346 | Food Effect Study of AG-221 in Healthy Male Subjects | COMPLETED | PHASE1 | 2014-08 | 2015-03 | 2014-12 |
| NCT02149966 | A Phase I Study of AG-348 in Healthy Volunteers | COMPLETED | PHASE1 | 2014-05 | 2014-11 | 2014-11 |
| NCT02108106 | A Phase I Study of AG-348 in Healthy Volunteers | COMPLETED | PHASE1 | 2014-03 | 2014-08 | 2014-08 |